> ## Content Index > Fetch the complete content index at: https://newsletters.qs.com/llms.txt > Use this file to discover other available public pages before exploring further. # 💊 Health Futures #35 - URL: https://newsletters.qs.com/health-futures-35/ - Published: 2024-09-16T11:30:32.000Z - Updated: 2024-09-16T11:30:33.000Z - Description: HolonIQ's Health Newsletter covers the latest developments in health devices, pharmaceuticals, and drug discovery and highlights the week's top health deals. - Author: QS - Tags: Health Skills **Happy Monday 👋** This week’s health newsletter highlights major themes Drug Production, Health Devices, and Drug Discovery. In Drug production, Vir Biotechnology [finalized](https://www.investing.com/news/company-news/vir-biotechnology-secures-sanofi-cancer-drug-licenses-93CH-3608174?ref=newsletters.qs.com) a licensing deal with Sanofi to acquire three clinical-stage therapies aimed at treating cancer. Innovations continue to make strides in MedTech as THINK Surgical [completed](https://www.prnewswire.com/news-releases/think-surgical-announces-first-use-of-its-tmini-miniature-robotic-system-with-new-features-302239199.html?ref=newsletters.qs.com) the first total knee arthroplasty procedure using its miniature Robotic System. In biotechnology, Summit Therapeutics released [positive results](https://finance.yahoo.com/news/summit-therapeutics-buy-now-082700426.html?ref=newsletters.qs.com) for its experimental cancer therapy compared to Keytruda. On the other hand, AstraZeneca’s lung cancer drug [failed](https://health.economictimes.indiatimes.com/news/pharma/research-development/astrazeneca-says-lung-cancer-drug-trial-shows-no-significant-improvement-in-overall-survival/113209007?ref=newsletters.qs.com) to show significant results as it didn’t improve the overall survival results of the patients. In health funding, Orlando Health acquired Sebastian River Medical Center and two other healthcare hospitals for[ $439M](https://www.sebastiandaily.com/business/orlando-health-successfully-acquires-sebastian-river-medical-center-for-439m-69711/?ref=newsletters.qs.com). ## 💊 Pharmaceuticals 🔬 **Vir Biotechnology finalized a licensing deal with Sanofi.** The [agreement](https://www.investing.com/news/company-news/vir-biotechnology-secures-sanofi-cancer-drug-licenses-93CH-3608174?ref=newsletters.qs.com) aimsto grant three clinical-stage therapies to treat cancer, including access to Sanofi's platform designed to enhance the delivery and effectiveness of T-cell engagers in oncology and infectious disease treatments. 🦠 **Hyundai Bioscience's Xafty shown promise as a broad-spectrum antiviral drug.** The drug has[ proven](https://www.prnewswire.com/news-releases/hyundai-bioscience-announces-xafty-a-groundbreaking-broad-spectrum-antiviral-capable-of-treating-covid-19-mpox-and-dengue-302244864.html?ref=newsletters.qs.com) effective against infections, including COVID-19, mpox, and dengue fever. The company is to supply the drug to countries facing a public health crisis. 💊 **Novo Nordisk** [**developed**](https://www.statnews.com/2024/09/10/novo-nordisk-amylin-pill-weight-loss-study/?ref=newsletters.qs.com) **a new daily weight loss pill.** The weight loss drug called Amycretin showed greater efficacy than its existing drug Wegovy in a clinical trial. ## 💻 Health Devices 💉 **THINK Surgical completed the first total knee arthroplasty procedure.** The surgical was [completed](https://www.prnewswire.com/news-releases/think-surgical-announces-first-use-of-its-tmini-miniature-robotic-system-with-new-features-302239199.html?ref=newsletters.qs.com) using its new TMINI Miniature Robotic System version 1.1 empowered surgeons to tailor the implant to the patient's needs. ⌚ **Neurode** [**developed**](https://techcrunch.com/2024/09/10/neurode-wants-to-treat-and-track-adhd-symptoms-through-a-wearable-headband/?ref=newsletters.qs.com) **a wearable headband.** The device can track and treat ADHD symptoms. The headband uses light electrical stimulation to balance the brain hence the device is currently seeking FDA approval. 🩺 **Proprio's surgical platform, Paradigm completed 50 successful surgeries.** The platform [provides](https://www.prnewswire.com/news-releases/proprio-successfully-completes-50-surgeries-using-first-ai-powered-surgical-platform-unveils-massive-dataset-302242958.html?ref=newsletters.qs.com) surgeons with real-time 3D anatomical mapping and is used in a variety of complex spinal surgeries. ## 🧪 Drug Discovery **🧫 Gilead Sciences partners with Genesis Therapeutics.** This strategic [collaboration](https://www.thepharmaletter.com/gilead-and-genesis-link-up-on-small-molecules?ref=newsletters.qs.com) is to discover and develop novel, small-molecule therapies across multiple targets. 🧬 **Carisma Therapeutics and Moderna** [**expanded**](https://www.prnewswire.com/news-releases/carisma-and-moderna-expand-collaboration-to-develop-two-in-vivo-car-m-therapies-for-autoimmune-diseases-302242590.html?ref=newsletters.qs.com) **their partnership.** Focusingon developing novel in-vivo macrophage engineering approaches for autoimmune diseases. **🩹 Summit Therapeutics released positive** [**results**](https://finance.yahoo.com/news/summit-therapeutics-buy-now-082700426.html?ref=newsletters.qs.com) **for its experimental cancer therapy.** Cancer therapy, ivonescimab showed superior efficacy compared to Keytruda in treating first-line lung cancer patients. However, AstraZeneca's experimental [cancer drug](https://health.economictimes.indiatimes.com/news/pharma/research-development/astrazeneca-says-lung-cancer-drug-trial-shows-no-significant-improvement-in-overall-survival/113209007?ref=newsletters.qs.com) did not significantly improve overall survival in patients with non-small cell lung cancer. ## **💰** Deals of the Week 🏥 **Orlando Health** acquired **Sebastian River Medical Center** and two other Steward Health Care hospitals for [$439M](https://www.sebastiandaily.com/business/orlando-health-successfully-acquires-sebastian-river-medical-center-for-439m-69711/?ref=newsletters.qs.com) continuing to expand its healthcare services in Florida. 💊 **Candid Therapeutics** raised [$370M](https://www.finsmes.com/2024/09/candid-therapeutics-raises-370m-in-funding.html?ref=newsletters.qs.com) in funding aiming to develop potentially transformative drugs to address autoimmune diseases. 🏣 **PanTera** secured [$102M](https://www.finsmes.com/2024/09/pantera-raises-e93m-in-series-a-funding.html?ref=newsletters.qs.com) in Series A funding intending to allocate the funds to support the construction of a production facility in Belgium. 🧬 **Superluminal Medicines** closed a[ $120M](https://www.thepharmaletter.com/series-a-supercharges-superluminals-gpcr-mission?ref=newsletters.qs.com) Series A funding round. The funds will support the development of its lead drug discovery program and expand its focus on GPCR targets. 🔬 **OrsoBio** secured a [$67M](https://www.finsmes.com/2024/09/orsobio-raises-67m-in-series-b-financing.html?ref=newsletters.qs.com) Series B funding. The funds will be used to accelerate the development of its mitochondrial protonophore portfolio for obesity and associated metabolic disorders. --- **Thank you for reading. Have a great week ahead!** Have some feedback or suggestions? Let us know at hello@holoniq.com [ ](https://newsletters.qs.com/psychedelic-mental-health-treatments-south-asia-health-tech-100-2/)